History
  • No items yet
midpage
916 F.3d 975
Fed. Cir.
2019
Read the full case

Background

  • Katten Muchin Rosenman LLP (Katten) represented Bausch & Lomb in an ongoing trademark matter and signed an engagement letter that referenced Valeant Pharmaceuticals International, Inc. (Valeant-CA) and incorporated Valeant’s Outside Counsel Guidelines (OC Guidelines).
  • The OC Guidelines stated they govern Valeant-DE, its subsidiaries and affiliates, required conflict checks before representation, and demanded heightened loyalty from “key firms.”
  • Attorneys Deepro Mukerjee and Lance Soderstrom moved from Alston & Bird to Katten on May 3, 2018; they previously represented Mylan in district and PTAB proceedings involving patents owned or licensed to Valeant affiliates (Valeant-CA, Salix, Dr. Falk).
  • Valeant-CA and Salix moved to disqualify Katten from representing Mylan in three appeals (Valeant II, Salix II, Dr. Falk II), arguing Katten’s ongoing representation of Bausch & Lomb (a Valeant affiliate) creates a concurrent conflict under Model Rule 1.7.
  • The court found the engagement letter and OC Guidelines created an ongoing attorney-client relationship extending to Valeant-CA and its subsidiaries, and independently found the affiliates (Valeant-CA, Salix, Bausch & Lomb) were sufficiently interrelated (shared infrastructure, common in-house legal, financial interdependence) to establish a corporate-affiliate conflict.
  • The court concluded Katten violated Rule 1.7 by representing Mylan adverse to Valeant-affiliates without informed, written consent and granted the motions to disqualify.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
Whether Katten’s engagement letter/OC Guidelines created an ongoing attorney-client relationship with Valeant-CA and its subsidiaries Engagement letter + OC Guidelines establish Katten represents Valeant-CA and affiliates, creating a conflict Engagement letter governs only Bausch & Lomb; OC Guidelines only restrict “key firms,” and Katten is not a key firm The engagement letter and OC Guidelines created an ongoing relationship with Valeant-CA and subsidiaries; Katten’s representation of Mylan is conflicted
Whether affiliates (Valeant-CA, Salix, Bausch & Lomb) are so interrelated that representing one is equivalent to representing all Affiliates share operations, legal department, employees, and financial ties — creating an affiliate conflict Representation of Bausch & Lomb does not automatically bind other affiliates absent clear agreement Affiliates are sufficiently interrelated (operational commonality and financial dependence) to give rise to corporate-affiliate conflict
Whether Katten’s post-hire ethical wall cures the conflict or avoids disqualification Ethical wall and adherence to rules mitigate conflict Ethical wall insufficient because created after the move, partial in scope, and no prior notice or waiver Ethical wall inadequate; disqualification warranted despite wall
Whether disqualification is required or discretionary given Rule 1.7 violation Disqualification unnecessary under balancing of circumstances and prejudice Disqualification appropriate to protect client loyalty and avoid conflict Court disqualified Katten — even if balancing were required, factors favored disqualification

Key Cases Cited

  • Celgard, LLC v. LG Chem, Ltd., [citation="594 F. App'x 669"] (Fed. Cir.) (apply regional circuit law and look to total context for disqualification analysis)
  • Atasi Corp. v. Seagate Tech., 847 F.2d 826 (Fed. Cir.) (regional circuit law governs professional conduct issues on appeal)
  • GSI Commerce Sols., Inc. v. BabyCenter, LLC, 618 F.3d 204 (2d Cir.) (factors for when affiliates are so interrelated that representing one implicates loyalty to another)
Read the full case

Case Details

Case Name: Dr. Falk Pharma Gmbh v. Generico, LLC
Court Name: Court of Appeals for the Federal Circuit
Date Published: Feb 8, 2019
Citations: 916 F.3d 975; 2017-2312; 2017-2636, 2018-1320; 2018-2097
Docket Number: 2017-2312; 2017-2636, 2018-1320; 2018-2097
Court Abbreviation: Fed. Cir.
Log In
    Dr. Falk Pharma Gmbh v. Generico, LLC, 916 F.3d 975